- Active not recruitingPHASE1
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This study looked at a new drug, tolinapant, combined with Decitabine and Cedazuridine, for people with a difficult-to-treat type of blood cancer called peripheral T-cell lymphoma. Researchers wanted to understand if the drug combination was safe and how well it worked. The study was stopped early because a safe dose couldn't be found.
For: Relapsed/Refractory Peripheral T-cell LymphomaUnited States · Australia · France - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
This study is testing a new medicine, Tolinapant, for people with advanced cancers like some solid tumours and lymphomas. The main goal is to check how safe it is and how the body handles the medicine. It also looks at whether the medicine helps to shrink tumours.
For: Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma · #2:Relapsed/refractory diffuse large B-cell lymphoma · #3:ProgressiveSpain · Italy